Laura Rodríguez
@laurg87Partner at Invivo Partners. PhD in Biotechnology.
Similar User
@LaiaArnal
@LauraSoucek
@AsabysPartners
@biocat_en
@abarberalluis
@eplorans
@Genesis_Biomed
@loopdx
@Sylvain_Sachot
@rkusW
@Anna_R_G
@ADmitTherapeut1
@EnriqueHeMoebio
@biofarmjlc
@jauamat
EVENT: Today, @laurg87 participated in the roundtable organized by @Itemas on "The Role of Institutions in Participated Companies", alongside @AnaRodriguezC11, Rafael Mañez (@Remabtx) , and @ypuiggros (@PwC_Spain), moderated by Lluís Blanch (@Itemas) y Ramon Maspons (@AQuAScat)
Cerramos la mañana hablando sobre el rol de las instituciones en empresas participadas con: ✅@AnaRodriguezC11 (consultora) ✅ @laurg87 (@InvivoPartners) ✅ Rafael Máñez (@Remabtx) ✅ @ypuiggros (@PwC_Spain) Moderan Lluís Blanch (ITEMAS) y Ramon Maspons (@AQuAScat)
Engaging discussion on challenges, trends, and value drivers shaping the C> space, and the potential growth opportunities in Europe at #ATE24 At @InvivoPartners , we believe the C> field will advance into new indications, novel cell types, and cutting-edge technologies.
Lovely summary by Drs Luis Pareras and Cinta Díez at @InvivoPartners in interesting strategies to bypass T cell dysfunction!!! Just amplifying their ideas/concepts of interest!!!
I'm delighted to be speaking at Advanced Therapies Europe, September 2024. Register now to join me at the No.1 event for the Cell & Gene Therapy industry! #ATE24 invt.io/1txb0k728iy
Laura Rodríguez @laurg87 will participate at the Oncology Innovation Panel with Ines Ullmo, Bettina Ernst, Ruben Sebastian-Perez & Marc Ramis, moderated by Juan R. Garcia, to discuss new technologies disrupting the oncology space at #RESIEurope24, Monday the 17th at 10 am.
EVENTS: Join Laura Rodríguez @laurg87, Partner and Gemma Guinart @gemmagnrt, Principal at Invivo Partners, at #AseBioID24 organized by @AseBio! Ready to engage with the Spanish Biotech ecosystem!
EVENTS: Laura Rodríguez , Partner and Gemma Guinart, Principal at Invivo Partners are attending #BioEquity! Eager to make new connections with the Biotech community.
PORTFOLIO NEWS: Our portfolio company @onechaintx has announced the first patient dosed in the #CARxALL clinical trial evaluating its most advanced product, OC-1 for a rare and aggressive subtype of leukaemia.
📣 Milestone Achieved! We've treated the first patient in our CARxALL trial with our most avanced product, OC-1. This marks a significant step forward in the fight against cortical T-cell acute lymphoblastic #leukemia More info here 👉 onechaintx.com/press/first-pa…
Yesterday, @laurg87, Partner at Invivo, participated in a roundtable with Marina Rigau (@mimarkdx) and Antoni Rosselló (@rcd_legal). The discussion, moderated by Adrià Escolà & Judit Domingo, focused on the three perspectives of an investment round. 1st #VenturesSummitVH @VHIR_
INTERNSHIP OPPORTUNITY: Are you willing to start a career in the #VentureCapital space? Apply now! 🗓Deadline extended to May 3rd!🗓 linkedin.com/posts/invivopa…
INTERNSHIP OPPORTUNITY: Are you willing to start a career in the hashtag#VentureCapital space? Our internship program is now open. Apply now! 🗓Deadline for applications: April 29th 2024. #InternshipOpportunity #VC linkedin.com/feed/update/ur…
PORTFOLIO NEWS: Welcome Michael Tadros, new CEO at Telomere. With his vast expertise in science, tech transfer, and biotech management, we're set to advance our gene therapy programs, targeting age-related diseases. linkedin.com/feed/update/ur…
PORTFOLIO NEWS: Excited to welcome Subhendu Basu as CEO of @Telum_Tx With 20+ years in biotech and pharma, his leadership will drive growth through partnerships, innovation, and expansion. Thrilled to have him on board for Telum's promising future. linkedin.com/posts/invivopa…
Big News! Thrilled to announce @gemmagnrt Gemma Guinart Mola's promotion to Principal at Invivo Partners! After years of great work, she's now set to lead with excellence. Congrats, Gemma!
Honored to step into my new role as Partner at @InvivoPartners, as we announce the preparation of a €100M 3rd Fund to nurture the next wave of innovation in life sciences, with a focus on ATMPs, synbio, and AI. Excited for the road ahead and the impact we'll make together.
INVIVO III/ Thrilled to announce we are preparing the closing of III fund, aiming for €100-120M (cell & gene therapy + synthetic biology + AI). @laurg87 is now Partner. Having Laura is a privilege; she stands out as one of the most talented individuals I have ever encountered.
INVIVO III/ Thrilled to announce we are preparing the closing of III fund, aiming for €100-120M (cell & gene therapy + synthetic biology + AI). @laurg87 is now Partner. Having Laura is a privilege; she stands out as one of the most talented individuals I have ever encountered.
PORTFOLIO NEWS: @onechaintx secured ~ €2M from the Spanish Ministry of Science and Innovation, propelling a second CAR T candidate for T-ALL from preclinical to clinical stage—a significant advance in treating this rare disease. linkedin.com/feed/update/ur…
PORTFOLIO NEWS: @Arthexbiotech has secured FDA clearance for Phase I-IIa trials of ATX-01 in Myotonic Dystrophy Type 1. ATX-01 represents a pioneering approach in microRNA therapeutics. Patient enrollment begins Q2 2024. lc.cx/bXvQe0
EVENTS: Today, Luis @pareras, Managing Partner at Invivo Partners, participates at a round table with Esteve Trias, Sol Ruiz, Matias Olsen, and Joana Silveira, to discuss New legal frameworks and the future of Advanced Therapies, at the Presentation of the 2023 #BioRegionReport
2⃣ Opening a debate on the legal framework of Advanced Therapies and personalized medicine. 👥 With: Matías Olsen (@EUCOP) Sol Ruiz (@AEMPSGOB) Joana Silveira (@Cuatrecasas) Lluís Pareras (Invivo Capital) 👉 Moderator: Esteve Trias (@Leitat) #BioRegionReport #ATMPs @AlmirallUS
Delighted to welcome Stefanos Theoharis as the new CEO of @onechaintx . With his unique blend of scientific expertise and business acumen, Stefanos is the ideal leader to drive OneChain's next phase of growth.
PORTFOLIO NEWS: We are excited to announce Stefanos Theoharis as new CEO of @onechaintx Stefanos brings a remarkable blend of scientific insight and business expertise and his leadership sets the stage for OneChain's next growth chapter.
United States Trends
- 1. Bo Nix 8.190 posts
- 2. Falcons 14,8 B posts
- 3. Ravens 82,4 B posts
- 4. Steelers 116 B posts
- 5. Chiefs 66,3 B posts
- 6. Paige 16,8 B posts
- 7. Bears 116 B posts
- 8. Packers 75,1 B posts
- 9. Broncos 22,8 B posts
- 10. WWIII 57,2 B posts
- 11. Bills 104 B posts
- 12. Jets 58 B posts
- 13. Lamar 32,6 B posts
- 14. Jennings 8.666 posts
- 15. Mahomes 20,2 B posts
- 16. Josh Allen 7.879 posts
- 17. Randle 11,9 B posts
- 18. Worthy 48,6 B posts
- 19. #HereWeGo 20,3 B posts
- 20. #GoPackGo 10,1 B posts
Who to follow
-
Laia Arnal Arasa
@LaiaArnal -
Laura Soucek
@LauraSoucek -
ASABYS PARTNERS
@AsabysPartners -
Biocat
@biocat_en -
Albert Barberà 🏳️🌈
@abarberalluis -
JMesa
@eplorans -
GENESIS Biomed
@Genesis_Biomed -
Loop-Dx
@loopdx -
Sylvain Sachot
@Sylvain_Sachot -
Markus Wilhelms
@rkusW -
Anna Riera
@Anna_R_G -
ADmit Therapeutics
@ADmitTherapeut1 -
Enrique Hernández
@EnriqueHeMoebio -
José Luis Cabero
@biofarmjlc -
Jaume Amat
@jauamat
Something went wrong.
Something went wrong.